First treatment with immunotherapy for advanced lung cancer with low pd-l1
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This study looks at how well immunotherapy works as the first treatment for people with advanced non-small cell lung cancer that has a low PD-L1 level. It aims to understand the benefits and side effects in this specific group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- Your lung cancer is 'non-small cell' type and has spread locally or to other parts of the body (stage IIIB, IIIC, or IV), so it can't be cured with surgery or radiation/chemo
- Your cancer does not have changes in the EGFR or ALK genes (called wild-type)
- Your cancer is PD-L1 negative (this means a lab test showed very low or no PD-L1 protein)
- You are receiving or will start immunotherapy (like PD-1 or PD-L1 inhibitors) as your first treatment for this cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
This trial tests two different immunotherapy medicines (AK104 and tislelizumab) combined with chemotherapy as the first treatment for people with advanced lung cancer that hasn't spread to the brain and has low PD-L1. The goal is to see which combination works better and if it helps people live longer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.